Ambien Articles
Generic drugs "saved USA $734B" since 1999, GPhA says, more than cost of TARP bank bail out
11 May 2009
Lunesta misses Ph II efficacy endpoints
16 March 2009
Survey finds US mail order patients switch to generics
29 September 2008
Transcept takes over Novacea in all-stock deal
8 September 2008
Sanofi-Aventis' second-quarter 2008 results disappoint analysts, hit by weak US dollar
11 August 2008
DEA block to US e-Rx adoption set to end
30 June 2008
Sanofi-Aventis
5 May 2008
US drug prices before elections provokes voter ire
3 March 2008
Neurogen refocuses R&D after cutting costs
25 February 2008
Ambien CR raises sleep time in insomnia with GAD
14 January 2008
BBC documents ReGen's zolpidem study
21 November 2007
Ambien CR improves output and time management
5 November 2007
Orexo's Sublinox shows positive results in Ph III
8 October 2007
Sanofi and Actelion will dominate insomnia market by 2016
3 September 2007
ReGen's zolpidem non-sedating in antidormancy trial
3 September 2007
Neurocrine resubmits indiplon NDA
3 September 2007
Web Rx drugs: "complex and emerging problem"
23 July 2007
Dr Reddy's launches generic zolpidem
30 April 2007
Barr confirms Ambien patent challenge
16 April 2007
Bogus Canadian web pharmacy's death probe
2 April 2007
Lilly to buy Hypnion for access to drugs
12 March 2007
US FDA warns about misrepresented drugs bought over the Internet
26 February 2007
Analysts see 2007 as key for ReGen Thera
15 January 2007
Astellas' fiscal 06/07 first-half net sales rise 5%
20 November 2006
Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results
6 November 2006
Pfizer ends indiplon accord with Neurocrine
3 July 2006
Stock Commentary - Europe - week to May 22, 2006
29 May 2006
FDA delays indiplon, Neurocrine drops 62%
22 May 2006
Sanofi-Aventis wins Lovenox patent appeal
17 April 2006
Sanofi-Aventis sales slow on competition
6 February 2006
Japan stock market week to January 9
16 January 2006
FDA OKs Sanofi-Aventis' Ambien CR for insomnia
12 September 2005
Takeda R&D meeting focuses on insomnia treatment Rozeram
1 August 2005
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Biovail gets tentative FDA OK for generic Ambien
6 June 2005
Biovail gets FDA OK for generic zolpidem
6 June 2005
Sanofi-Aventis' Ambien "approvable"
18 April 2005
Fujisawa's 9-month sales rise 2.5%
21 February 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
Aspirations of Astellas Pharma, the merged Yamanouchi/Fujisawa
22 November 2004
US uninsured "pay 78% more than best Rx prices"
1 November 2004
Managed care "stalling US insomnia Rx market"
16 August 2004
Sanofi beats forecasts: 2nd-qtr sales up 19.4%
26 July 2004
Canadian web site: all drugs fake, substandard
26 July 2004
UK NICE guidance on insomnia drugs
10 May 2004
Detailing rejection of Sanofi bid, Aventis says it is opportunistic, under-values firm
15 March 2004
Sanofi-Synthelabo reveals R&D pipeline with nine compounds in Ph III
23 February 2004
Sanofi-Synthelabo's 2003 sales up 15.6%
26 January 2004
Sanofi sales strong but below expectations
27 October 2003
Sanofi-Synthelabo ups forecast on strong 1st-half, but fears persist over key patent
8 September 2003
Sanofi raises full-year earnings forecast
8 September 2003
Sales up 14% at Sanofi-Synthelabo in 1st half
28 July 2003
Sanofi-Synthelabo 1st qtr below consensus
5 May 2003
Update: Pharmacia's earnings match forecasts in 2002
24 February 2003
Pharmacia's earnings match forecasts in 2002
24 February 2003
Sepracor seeks US OK for eszopiclone
10 February 2003
53.7% US sales leap boosts Sanofi-Synthelabo
27 January 2003
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Sanofi-Synthelabo invests in Tours site expansion
25 February 2002
Sanofi-Synthelabo 2001 EPS leap 44%
25 February 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Biovail files new form of sleep drug zolpidem.
21 January 2002
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
